GlassScriptPhysician profile
Teodulo J Perez
NPI 1043817232
$6,869.26
in general payments reported to CMS, 2019-2025
23 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $750 · 2022: $1,406 · 2023: $1,496 · 2024: $1,729 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628 · Education: $86.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,627.50 |
| Education | $86.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,754.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,421.14 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $882.03 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $854.73 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $415.76 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Amgen INC. | $389.49 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $225.21 | 2023-2025 | Orladeyo |
| Optinose US, INC. | $210.46 | 2022-2025 | |
| Genentech USA, INC. | $127.54 | 2022-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $118.13 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $77.24 | 2025 | Neffy |
| Octapharma USA, INC. | $72.96 | 2021-2022 | |
| Pharming Healthcare, INC. | $50.85 | 2025 | Ruconest |
| Aimmune Therapeutics, INC. | $45.50 | 2022 | |
| Hikma Pharmaceuticals USA | $35.76 | 2024-2025 | Ryaltris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.53 | 2025 | Ebglyss |
| Grifols USA, LLC | $25.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.37 | 2021 | |
| Organon LLC | $24.47 | 2025 | Vtama |
| Horizon Therapeutics Plc | $23.71 | 2022 | |
| Tersera Therapeutics LLC | $21.57 | 2024 | Quzyttir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.68 | 2021 | |
| Aytu Biopharma, INC. | $16.30 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teodulo Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.